Neurocrine Biosciences NBIX Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:DeferredIncomeTaxAssetsNet.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's deferred tax assets?
- Neurocrine Biosciences (NBIX) reported deferred tax assets of $381.4M in Q1 2026.
- How has Neurocrine Biosciences's deferred tax assets changed year-over-year?
- Neurocrine Biosciences's deferred tax assets decreased by 23.6% year-over-year, from $499.4M to $381.4M.
- What is the long-term trend for Neurocrine Biosciences's deferred tax assets?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's deferred tax assets has grown at a 0.1% compound annual growth rate (CAGR), from $319.4M to $320.3M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.